Key Points
- COO Robert Ainscow sold 25,000 shares on March 6 at an average price of $4.51 for $112,750, cutting his stake by 1.63% to 1,512,817 shares (valued about $6.82M).
- ASP Isotopes missed on earnings with quarterly EPS of ($0.84) versus a ($0.14) estimate despite revenue of $33.32M (vs. $2.03M expected), and shows very poor profitability metrics (net margin -734.14%, ROE -307.82%).
- Several large institutions (Alyeska, Vanguard, Rovida, UBS, Geode) materially increased holdings recently, while analysts' consensus is a Hold with an average price target of $13.00.
ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) COO Robert Ainscow sold 25,000 shares of the company's stock in a transaction on Friday, March 6th. The stock was sold at an average price of $4.51, for a total value of $112,750.00. Following the sale, the chief operating officer owned 1,512,817 shares of the company's stock, valued at $6,822,804.67. This trade represents a 1.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Robert Ainscow also recently made the following trade(s):
- On Friday, March 6th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The stock was sold at an average price of $5.44, for a total value of $45,902.72.
ASP Isotopes Trading Down 1.2%
Shares of NASDAQ ASPI opened at $5.00 on Wednesday. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10. The stock has a market capitalization of $629.50 million, a P/E ratio of -2.34 and a beta of 3.59. ASP Isotopes Inc. has a 1-year low of $3.92 and a 1-year high of $14.49. The business has a fifty day moving average price of $5.08 and a 200 day moving average price of $6.79.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its quarterly earnings data on Friday, April 10th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.70). The company had revenue of $33.32 million for the quarter, compared to analysts' expectations of $2.03 million. ASP Isotopes had a negative return on equity of 307.82% and a negative net margin of 734.14%. Equities research analysts expect that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.
Institutional Investors Weigh In On ASP Isotopes
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. raised its stake in ASP Isotopes by 73.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company's stock valued at $26,191,000 after buying an additional 2,072,851 shares during the last quarter. Vanguard Group Inc. raised its stake in ASP Isotopes by 37.9% in the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company's stock valued at $43,451,000 after buying an additional 1,241,024 shares during the last quarter. Rovida Investment Management Ltd raised its stake in ASP Isotopes by 28.1% in the fourth quarter. Rovida Investment Management Ltd now owns 4,100,000 shares of the company's stock valued at $21,894,000 after buying an additional 900,000 shares during the last quarter. UBS Group AG raised its stake in ASP Isotopes by 150.3% in the fourth quarter. UBS Group AG now owns 2,406,457 shares of the company's stock valued at $12,875,000 after buying an additional 1,445,165 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in ASP Isotopes by 28.0% in the fourth quarter. Geode Capital Management LLC now owns 2,384,066 shares of the company's stock valued at $12,758,000 after buying an additional 521,611 shares during the last quarter. 16.80% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of ASP Isotopes in a research note on Friday, March 27th. Canaccord Genuity Group restated a "buy" rating and set a $11.00 price objective on shares of ASP Isotopes in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $13.00.
View Our Latest Research Report on ASP Isotopes
ASP Isotopes Company Profile
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
